Can probiotics cure dysbiosis?

Not alone. Probiotics are supportive, not curative. They work when host capacity is intact or recovering, dysbiotic species have been suppressed, the barrier is healing, and the diet supports beneficial bacteria. They fail when colonocyte bioenergetics are still depleted or when introduced before antimicrobial suppression.

Why don't probiotics fix dysbiosis on their own?

Probiotics introduce beneficial bacteria but cannot restore colonocyte mitochondrial function, repair tight junctions, or reverse NAD+ depletion. Without host-side restoration, beneficial bacteria can't establish — the ecological niche that supports them is missing.

What causes treatment-refractory dysbiosis?

Persistent colonocyte bioenergetic failure. As long as NAD+ is depleted and mitochondrial function is impaired, the gut barrier remains compromised and dysbiotic species keep the ecological advantage. Refractory dysbiosis is almost always a Host Capacity problem, not a bacterial-resistance problem.

How does the Host Capacity Model reframe dysbiosis?

Standard models treat dysbiotic bacteria as the disease. The Host Capacity Model treats dysbiosis as the symptom of an upstream colonocyte energy crisis. Restore the host — NAD+, butyrate, barrier, mitochondrial cofactors — and dysbiosis resolves because the ecological pressure that selected for it is gone.

Can the gut barrier be restored?

Barrier repair depends on colonocyte bioenergetics. Tight junction proteins (claudins, ZO-1) are ATP-dependent, so restoring energy supply is the mechanistic precondition for repair. This is a mechanistic inference from the published literature, not a measured BiomeLogic outcome, and specific interventions are a question for your own licensed clinician.

How long does dysbiosis recovery take?

There is no reliable general answer, and BiomeLogic has no measured recovery-time data. Published courses vary widely by driver, and the mechanistic expectation is simply that host-side recovery is slower than any change in bacterial load. Anyone quoting a fixed week-by-week timeline is describing a template, not your case.

Condition framework

Treatment-Refractory Dysbiosis: Why Probiotics Failed

Why standard dysbiosis protocols fail in chronic cases, and how the Host Capacity Model and ecological thermodynamics reframe restoration of the gut microbiome.

What is dysbiosis — and why conventional treatment fails

Dysbiosis is an alteration in the microbial community: ↓ beneficial bacteria (Faecalibacterium, Roseburia, Akkermansia), ↑ pathogenic bacteria (Klebsiella, Citrobacter, Desulfovibrio), loss of microbial diversity, altered metabolite production (↓ butyrate, ↑ secondary bile acids, ↑ LPS), and increased intestinal permeability.

Standard treatment kills bacteria with antibiotics, herbals, or restrictive diet. But it doesn't address why bacteria overgrew in the first place. Dysbiosis recurs because the host capacity — the colonocyte's ability to maintain a healthy environment — never recovered.

The Host Capacity Model: dysbiotic bacteria are secondary. The primary lesion is colonocyte bioenergetic failure. Restore the host, and dysbiosis resolves.

The cascade: how dysbiosis develops

Step 1: Colonocyte bioenergetic crisis. Colonocytes depend on mitochondrial ATP for tight junctions, mucus secretion, antimicrobial peptide synthesis, and barrier function. When mitochondrial function fails — from CD38-driven NAD+ depletion, Complex I/II impairment, SIRT3 loss, Fe-S cluster failure — colonocytes can no longer maintain the environment.

Step 2: Barrier collapse. Tight junctions break down, the mucus layer thins, antimicrobial defenses decline, permeability increases. Dysbiotic species preferentially exploit this — fast-growing gram-negatives (Klebsiella, Citrobacter), H₂S-producers (Desulfovibrio), methanogens (Methanobrevibacter smithii).

Step 3: Dysbiotic metabolites. ↓ Butyrate (Faecalibacterium, Roseburia loss). ↑ Secondary bile acids. ↑ H₂S. ↑ D-lactate. ↑ LPS. ↑ Uremia from dysbiotic proteolysis.

Step 4: Endotoxemia loop. LPS translocation triggers IL-6, TNF-α, IL-1β production via TLR4. This perpetuates CD38 upregulation and consumes more NAD+, closing the loop. Dysbiosis perpetuates the very bioenergetic failure that created it.

Phase 1: Bioenergetic assessment

Identify the specific energy bottleneck driving dysbiosis. Panel: Organic Acid Test; intracellular NAD+ panel; mitochondrial markers (lactate, carnitine, CoQ10); Fe-S cluster proxies (iron, B2, B3); inflammation and barrier (hs-CRP, LPS/LBP, zonulin, calprotectin). If NAD+ is depleted and inflammation is high, prioritize anti-inflammatory and NAD+ restoration.

Phase 2: Dysbiotic ecosystem mapping

Shotgun metagenomics for full species and functional gene profile. Quantitative SCFA panel for butyrate production. Barrier markers — zonulin, calprotectin, LPS/LBP. Interpretation: high Klebsiella + low Faecalibacterium + low butyrate = advanced gram-negative dysbiosis. High Desulfovibrio + neurological symptoms = H₂S-driven dysbiosis. High calprotectin + high zonulin = active dysbiosis-driven inflammation.

Phase 3: What restoration has to address

This section deliberately names mechanistic targets rather than agents, doses, or a week-by-week schedule. BiomeLogic is a non-clinical educational site and holds no measured outcome data for any regimen; what follows is the reasoning a clinician can work from, not a protocol to follow.

Reduce the fermentative and inflammatory load. Whether that is achieved with antimicrobials, botanicals, or dietary change is a clinical decision. Mechanistically the point is only to relieve the pressure that keeps LPS translocation and cytokine-driven CD38 upregulation running.

Restore colonocyte energy supply. The NAD+ pool, butyrate availability, and mitochondrial cofactor status are the levers the model treats as upstream. Evidence class here is mechanistic inference plus indirect human data — not established human outcome evidence for the combination.

Support barrier repair. Tight-junction integrity is ATP-dependent, so barrier work that is not preceded by energy restoration is expected to stall. This is a prediction of the model, and it is falsifiable.

Phase 4: Judging whether anything changed

Reassessment matters more than any single intervention. The measures that speak to the model are the ones tracking host capacity and ecology together — NAD+ status, butyrate-producer abundance, and barrier markers such as zonulin and calprotectin — rather than symptom relief alone.

If host capacity is recovering and the dysbiotic pattern is not, the model is wrong for that case and the driver lies elsewhere. That is the honest test. Which measures to run, how often, and what to do with the results are questions for your own licensed clinician.

Frequently asked questions

Bring a case for mechanistic review.

Request a Consultation